They could also act as epigenetic drugs, reverting the acquired epigenetic changes associated with tumor resistance to therapy such as the promoter methylation of suppressor genes, inhibition of DNMTs activity, and HDAC regulation through methylation. This evidence concerns the gene HDAC9 and neoplasm.